MyFinsight
Home
Blog
About
Contact
Download
Download image
Comprehensive loss
-$37,927K
(7.91%↑ Y/Y)
Net loss
-$37,605K
(8.60%↑ Y/Y)
Unrealized losses on
available-for-sale securities
-$322K
(-725.64%↓ Y/Y)
Product IBSRELA
$70,074K
Product XPHOZAH
$23,299K
License Agreement
Development...
$352K
Kyowa Kirin
Co.Ltd-License Agreement...
$2K
Knight Therapeutics
Inc-License Agreement...
$31K
License Agreement
Development...
$20K
Loss before
provision for income taxes
-$37,597K
(6.67%↑ Y/Y)
Provision for income taxes
$8K
(-99.07%↓ Y/Y)
Other income, net
$2,112K
(-9.20%↓ Y/Y)
Product
$93,373K
(37.69%↑ Y/Y)
Non Cash Royalty
Related To Sale Of Future...
$695K
(-32.26%↓ Y/Y)
Product Supply Revenue
$354K
(39.37%↑ Y/Y)
License
$51K
(-98.98%↓ Y/Y)
Gain from operations
-$32,793K
(9.78%↑ Y/Y)
Interest expense
$5,599K
(33.60%↑ Y/Y)
Total revenues
$94,473K
(27.47%↑ Y/Y)
Non-cash interest
expense related to the...
$1,317K
(-36.41%↓ Y/Y)
Total costs and
operating expenses
$127,266K
(29.65%↑ Y/Y)
Selling, general and
administrative
$102,267K
(22.88%↑ Y/Y)
Research and development
$20,188K
(35.15%↑ Y/Y)
Cost of sales
$4,811K
(-60.90%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
ARDELYX, INC. (ARDX)
ARDELYX, INC. (ARDX)